New drug ripertamab tested for muscle weakness disease
NCT ID NCT07372807
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests whether a single infusion of ripertamab can safely improve daily living activities in 20 adults with generalized myasthenia gravis, a condition causing muscle weakness. Participants are randomly assigned to receive the drug or a placebo, and are followed for 13 weeks to track symptom changes and any medical problems.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ripertamab (a drug given as a single intravenous infusion)
- What this could lead to
- If it works, this could point toward a new treatment option to control symptoms of generalized myasthenia gravis.
- What could go wrong
- This is an early Phase 1/2 trial with only 20 participants, so results may not apply to everyone. The drug may not improve symptoms or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS (MG) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking daily life unlock myasthenia gravis mysteries?
- Hidden toll of myasthenia gravis: study probes sexual and bladder problems often overlooked
- Engineered immune cells take aim at autoimmune diseases
- New drug aims to ease daily struggles of myasthenia gravis
- New drug MTM-H-001 targets B-Cell autoimmune diseases in early trial
- New study aims to uncover hidden clues in myasthenia gravis